Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigating Mechanisms That Dictates Tumor Immunogenicity and Exploring Biomarkers That Could Help Predict the Anti-tumor Immune Response in Patients With Cervical Cancer

NCT05188716 is registered in ClinicalTrials.gov with Chuangzhen Chen as lead sponsor.

NCT NCT05188716
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05188716 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigating Mechanisms That Dictates Tumor Immunogenicity and Exploring Biomarkers That Could Help Predict the Anti-tumor Immune Response in Patients With Cervical Cancer
Lead sponsor
Chuangzhen Chen
Phase
Observational
Overall status
Completed
Start date
December 10, 2020
Completion date
January 15, 2022
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

benign tumor of uterus, cervical cancer